Dr. Reddy's and Alvotech have partnered to co-develop a biosimilar of Keytruda, Merck's $29.5 billion cancer drug, boosting ...

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Dr. Reddys shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit ...

Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Alvotech and Dr. Reddy's collaborate to develop biosimilar Keytruda, expanding global access to cancer treatment options.

Alvotech and Dr Reddy’s Laboratories announced today they have entered a collaboration agreement to co-develop, manufacture ...

Dr Reddy's shares soar 3.54% after Alvotech partnership for Keytruda biosimilar, enhancing global reach in cancer ...

Dr Reddy's Laboratories and Alvotech join forces to co-develop and commercialize a biosimilar to Keytruda (pembrolizumab) for ...